Emergent Biosolutions Inc (EBS) Quote

Taking my chances on IINN now

Probably a good idea

I am out. Will wait for a dip and jump back in later this year

You pays your monies and you takes your chances

GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent’s newly appointed president and CEO, Joseph C. Papa, will provide remarks.

Conference Call Information
Participants can access the conference call live via webcast from the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

When is the expected earnings report

Hope we see better than expected earnings report

EBS came up off the mat

Well alright then
Socially responsible company
We wait

After Market close

EBS 10Q 2/27

EBS: The hands-down WINNER of this day!!! EASY FRICKIN' MONEY!!!

EBS now No 1 on the Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

EBS No 3 on the Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

EBS: Got new CEO, who wants to drive this Firm to the BIG TIME!!

Lets see what happens when the financials are released. If they hit their sales target with the OTC Narcan, should be nice net profits, JMO

EBS new 52 week low

What is up with this company? Management gonna ride this into the ground and bury it?

EBS new 52 week low

EBS new 52 week low

EBS new 52 week low

Heaping pile of company. Haven’t seen this kind of incompetence in all my years of trading! Narcan everywhere! And this company is collapsing!

EBS new 52 week low

EBS new 52 week low

I’m starting to shift opinions on this… might be a turd of a company. There has to be something seriously rotten here for SP to plummet through 52 week lows.
GL

This has not gone the way it should.
Hmmm….

I’m sure a lot of competitors will try, but Narcan is proven, trusted and ahead of all of them. If this was a race, the $EBS horse is waaaay ahead. I’ve learned to stay clear from really long shot ideas that required a lot a praying. IMO, this is the horse to bet on, especially so near 52 week lows.
GL

Hi;
I’m long for EBS. I think it has great potential.
I just have a question. I’ve read that RiVive will come up with its own nasal narcan. Will this have significant impact on EBS?
Doc

18% short interest. This could run big into September when Narcan shows up in stores and gets local/national news
GL $EBS

Narcan for everybody!! $EBS

https://ih.advfn.com/stock-market/NYSE/emergent-biosolutions-EBS/stock-news/91689294/emergent-biosolutions-awarded-10-year-barda-contra

almost exactly 1 year later

Cali State of Emergency https://www.gov.ca.gov/2022/08/01/74502/

Looks like this sleeping Giant
Is getting ready to awake!
Let’s go $EBS

Building position

"Emergent was forced to halt operations at its plant in the Bayview area of Baltimore after contamination issues led to millions of spoiled vaccine doses."

https://www.nytimes.com/2021/06/16/us/emergent-biosolutions-covid-vaccine.html?action=click&module=Top%20Stories&pgtype=Homepage

since your recommendation, it has lost half its value.

Buy buy buy

One patient got sick out of 60,000.
Buy buy buy

Gift

EPS

2019 $2.88
2020 $6.59
2021 $7.96

P/E = 14.70 on next years earnings. Cheap stock compared to S &P which is in the mid 20’s depending on which one you use.

Cannon! Bull Flag Alert!!!!

Emergent BioSolutions Signs Development and Manufacturing Agreement with Vaxart for their Experimental Oral Vaccine Candidate for Coronavirus Disease



GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-market contract development and manufacturing (CDMO) services to develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease (COVID-19). Development services will begin immediately, and upon Vaxart’s election, Emergent agrees to produce clinical material expected to enable Vaxart to initiate a Phase 1 clinical study anticipated early in the second half of 2020. Vaxart’s oral recombinant vaccine candidate is based on its proprietary VAAST™ platform.

“Emergent is pleased to deploy our nimble CDMO expertise to support fellow innovators, like Vaxart, and advance an experimental COVID-19 vaccine candidate,” said Syed T. Husain, senior vice president and CDMO business unit head at Emergent BioSolutions. “We look forward to applying our broad molecule-to-market services, including our ability to work with a multitude of delivery systems, execute under expedited timelines, and meet Vaxart’s potential need for future scalability and large-scale capacity for commercial quantities.”
Under the terms of the agreement, Emergent will provide development services out of its Gaithersburg, Md. location and manufacture drug substance at its Bayview facility in Baltimore, Md., designated a Center for Innovation in Advanced Development and Manufacturing (CIADM) by the U.S. Department of Health and Human Services. Emergent’s Bayview CIADM is the same facility used to manufacture drug substance for the company’s recently announced Novavax collaboration. The facility has the capacity to produce tens to hundreds of millions of doses of vaccine on an annual basis, based upon the platform technology being leveraged. Additionally, it has the unique capability of producing at clinical scale, to get vaccine candidates quickly into the clinic, and in parallel, scaling up to produce commercial volumes to meet customer demand.

“I’m pleased that we are joining forces with an experienced manufacturer such as Emergent to help advance our oral COVID-19 vaccine to the clinic,” said Wouter Latour, MD, chief executive officer of Vaxart. “We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a large vaccination campaign, and Emergent is a great partner to help in this endeavor.”

About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our ability to advance potential solutions to combat coronavirus disease as well as the anticipated production level and use of the COVID-19 experimental vaccine candidate in a Phase 1 clinical study in the expected timeframe, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.
statements.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com

Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
KiefferL@ebsi.com

Don’t have the actual contract, but here’s the link to the PR >> https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-development-and-manufacturing-0

……………………....EPS
Mar 2020 04/30/2020 0.01
Dec 2019 02/20/2020 1.57
Sep 2019 11/06/2019 1.21
Jun 2019 08/01/2019 0.12

EBS CHART

Does any one know details of VXRT contract ?

PE Ratio = 76

EPS =1.03

Revenue = $ 1.11B

Market Cap=4.89 B

Yeah I’m not sure why it’s acting this way. Should go back up once news is out on JNJ study on Vaxart oral pill soon.